A Response to: Letter to the Editor Regarding 'Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age'
Infect Dis Ther
.
2023 Jan;12(1):295-298.
doi: 10.1007/s40121-022-00719-4.
Epub 2022 Nov 14.
Authors
Mark H Rozenbaum
1
,
Johnna Perdrizet
2
,
Xiuyan Li
2
,
Matt D Wasserman
3
,
Lindsay R Grant
4
,
Kyla Hayford
4
,
Raymond A Farkouh
5
Affiliations
1
Health Economics and Outcomes Research, Pfizer, Capelle aan den Ijssel, The Netherlands. Mark.rozenbaum@pfizer.com.
2
Health Economics and Outcomes Research, Pfizer Inc, New York, NY, USA.
3
Patient and Health Impact, Pfizer Inc, New York, NY, USA.
4
Vaccines Medical Development and Scientific and Clinical Affairs, Pfizer Inc, New York, NY, USA.
5
Health Economics and Outcomes Research, Pfizer, Capelle aan den Ijssel, The Netherlands.
PMID:
36376731
PMCID:
PMC9868018
DOI:
10.1007/s40121-022-00719-4
No abstract available
Publication types
Letter